Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Affiliations

Novartis Licenses Biomaterial for Cancer Immunotherapy

Drug maker Novartis is licensing from a lab at Harvard University a biocompatible material designed to provide delivery of treatments that invoke the immune system to fight cancer. . . . → Read More: Novartis Licenses Biomaterial for Cancer Immunotherapy

Crispr Techniques Devised for Editing RNA

Geneticists and bioengineers developed a technology for applying genomic editing techniques known as Crispr to ribonucleic acid, or RNA, transcribed from the genetic code in a person’s DNA. . . . → Read More: Crispr Techniques Devised for Editing RNA

Company Formed to Develop Cancer Cell Therapies

The MD Anderson Cancer Center in Houston is starting Optera Therapeutics Corp., a new company to commercialize its research on treating cancer with a patients’ own immune system cells. . . . → Read More: Company Formed to Develop Cancer Cell Therapies

Institute, Company Studying Neuro Disease Proteins

The Montreal Neurological Institute and Thermo Fisher Scientific are beginning a study of 30 proteins implicated in neurodegenerative diseases to validate related antibodies and reagents for advancing treatments. . . . → Read More: Institute, Company Studying Neuro Disease Proteins

3-D Biomaterial Boosts Personal Cancer Immunotherapy

A Harvard University bioengineering lab developed an injectable material designed to load up with proteins from a patient’s own tumors to induce immune reactions that fight that person’s cancer. . . . → Read More: 3-D Biomaterial Boosts Personal Cancer Immunotherapy

Breathalyzer Biopsy Company Gains $15M in New Funds

A company in the U.K. developing a technology for early and precise diagnosis of lung and other cancers by analyzing exhaled breath is raising $15 million in new venture capital. . . . → Read More: Breathalyzer Biopsy Company Gains $15M in New Funds

Trial Shows Reduction in Huntington Disease Protein

First results from a clinical trial show an experimental therapy reduces production of a protein damaging nerve cells in people with Huntington disease. . . . → Read More: Trial Shows Reduction in Huntington Disease Protein

Start-Up Developing Blood-Brain Barrier Treatments

A medical school professor in Singapore is starting a biotechnology company to discover and develop new drugs for neurological disorders based on his research with mechanisms for crossing the blood-brain barrier. . . . → Read More: Start-Up Developing Blood-Brain Barrier Treatments

Biotech Sponsoring Microbiome-Cancer Research

A biotechnology enterprise is starting research collaborations with cancer labs in the U.S. and Germany to study interactions of gut microbes on responses of individuals to cancer immunotherapies. . . . → Read More: Biotech Sponsoring Microbiome-Cancer Research

Synthetic Bio Company Starts Up, Raises $53 Million

A start-up business that aims to apply principles of computer circuit design to biology and medicine in creating treatments for disease is raising $53 million in its first venture funding round. . . . → Read More: Synthetic Bio Company Starts Up, Raises $53 Million